株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヘパリンの欧州市場 - 2016〜2024年:製品別・最終用途別業界分析、規模、シェア、成長、動向および予測

Heparin Market (Product - Low Molecular Weight Heparin, Unfractionated Heparin, Ultra-low Molecular Weight Heparin; End Applications - Hospitals, Blood and Stem Cell Bank) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

発行 Transparency Market Research 商品コード 335188
出版日 ページ情報 英文 101 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
ヘパリンの欧州市場 - 2016〜2024年:製品別・最終用途別業界分析、規模、シェア、成長、動向および予測 Heparin Market (Product - Low Molecular Weight Heparin, Unfractionated Heparin, Ultra-low Molecular Weight Heparin; End Applications - Hospitals, Blood and Stem Cell Bank) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024
出版日: 2016年08月29日 ページ情報: 英文 101 Pages
概要

当レポートでは、欧州のヘパリン市場について詳細に分析し、2016〜2024年の成長見通し、製品別、国別動向、および参入企業のプロファイルをまとめています。

第1章 はじめに

第2章 調査の前提条件および調査方法

第3章 エグゼクティブサマリー

第4章 市場概要

  • 製品概要
  • 主な業界内の出来事
  • 欧州における脳血管障害(CVD)の死亡率(2015年)
  • EUにおける主な死因
  • 医薬品支出(2013年および2014年)

第5章 市場力学

  • 市場促進因子と阻害因子の簡易分析
  • 市場促進因子
    • 欧州における凝固および腎疾患の発症率の上昇
    • 食肉処理業者が粗ヘパリン加工ビジネスに参入しようとしていることによる欧州の需給ギャップ解消の見込み
    • 中国からの輸入禁止が欧州での生産を促進
    • 安全でコスト効率の良いヘパリン製品の商品化
  • 市場阻害因子
    • 抗凝固剤代替製品の安定供給が生物学的ヘパリン製品の売上を阻害
    • 品質管理対策と環境対応の強化がヘパリン生産のコストを上げる
    • 特許権の失効と認可外製品の使用増
    • ヘパリン起因性血小板減少症のリスク
  • 市場の機会
    • 生物学的製品の代替品としてのバイオシミラー
    • 海洋ヘパリン製品に関する代替品研究
  • 機会分析
  • 価格徹底および市場予測

第6章 製品別市場

  • 主な調査結果
  • 市場価格シェアの分析
  • 市場規模予測
    • 低分子量ヘパリン
    • 非分画ヘパリン
    • 超低分子量ヘパリン
  • 主要動向
  • 市場の魅力度分析

第7章 エンドユーザー別市場

  • 主な調査結果
  • イントロダクション
  • 市場価格シェアの分析
  • 市場規模予測
    • 病院
    • 血液/幹細胞バンク
    • その他
  • 主要動向

第8章 国別市場

  • 市場価格のシェア分析
  • ドイツ
  • フライス
  • 英国
  • イタリア
  • スペイン
  • ポーランド
  • スイス
  • オーストリア
  • ハンガリー
  • ベルギー
  • ポルトガル
  • チェコ共和国
  • ギリシャ
  • スロバキア
  • 欧州のその他の国
  • 市場の魅力度分析

第9章 競合情勢

  • 企業別欧州市場のシェア
  • 競合マトリックス
    • Sanofi SA
    • GlaxoSmithKline plc
    • Pfizer, Inc.
    • Leo Pharma
    • Dr. Reddy's Laboratories
    • Fresenius SE & Co. KG
    • Teva Pharmaceutical Industries Ltd.

第10章 企業プロファイル

  • Sanofi SA
  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Leo Pharma
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co. KG
  • Teva Pharmaceutical Industries Ltd.

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

This report provides in-depth country wise analysis of the heparin market in Europe. Stakeholders of this report include manufacturers of heparin products, crude heparin suppliers, heparin processing companies, and new players planning to enter the market.

The report provides qualitative and quantitative analysis of the heparin market in Europe. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes market share held by companies in 2015, market size, and forecast for the heparin market in major countries in Europe such as Germany, France, the U.K., Italy, Spain, Poland, Switzerland, Austria, Hungary, Belgium, Portugal, the Czech Republic, Greece, Slovakia, and Rest of Europe from 2014 to 2024. Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the heparin market in Europe with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.

The market overview section comprises impact factors such as drivers, restraints, and opportunities for the heparin market in Europe. These factors would aid the stakeholders in establishing a strong foothold in Europe. Furthermore, the market overview section comprises key industry events, product overview, mortality rate of CVD in Europe, leading causes of death, and country-wise pharmaceutical expenditure. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments to identify the most attractive market.

Market share analysis is also provided in the competitive landscape section of the report for the year 2015 in terms of value (%). Furthermore, the report analyzes different heparin product types such as unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin. The product type section provides market analysis for different types of heparin in Europe. This includes an overview of product types, indications for use, presence of any biosimilars, market drivers, issues, and regulations amended for its production and use. Prices of products vary based on product type and formulation. Moreover, the heparin market by end-users such as hospitals, blood and stem cell banks, and others has also been analyzed in the report. The report provides average pricing analysis (based on the current prices) to offer an overview of prices of heparin-based pharmaceutical products in the EU (2015 & 2024).

The report provides market analysis for heparin in the major countries in the EU: Germany, France, the U.K., Italy, Spain, Poland, Switzerland, Austria, Hungary, Belgium, Portugal, the Czech Republic, Greece, Slovakia, and Rest of Europe. Market analysis for each of these countries has been provided from 2014 to 2024 along with the CAGR from 2016 to 2024. The market has been estimated for finished heparin formulation and has not considered its APIs. Major factors such as aging population and increasing prevalence of venous thromboembolism (VTE) that propel the market for heparin in Europe are elaborated in the report. This report also covers certain regulations governing the manufacture and import of heparin in some countries.

Major players operating in the heparin market in Europe such as Dr. Reddy's Laboratories Ltd., Leo Pharma, Pfizer, Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd. are profiled in this report.

The Europe heparin market is segmented into the following categories:

Europe Heparin Market, by Product

  • Unfractionated Heparin
  • Low Molecular Weight Heparin
  • Ultra-low Molecular Weight Heparin

Europe Heparin Market, by End-user

  • Hospitals
  • Blood and Stem Cell Banks
  • Others

Europe Heparin Market, by Country

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Poland
  • Switzerland
  • Austria
  • Hungary
  • Belgium
  • Portugal
  • Czech Republic
  • Greece
  • Slovakia
  • Rest of Europe

Table of Contents

1. Preface

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Objectives
  • 1.4. Key Questions Answered

2. Assumptions and Research Methodology

  • 2.1. Report Assumptions
  • 2.2. Acronyms Used
  • 2.3. Research Methodology

3. Executive Summary

  • 3.1. Europe Heparin Market Snapshot
  • 3.2. Key Trends

4. Market Overview

  • 4.1. Product Overview
  • 4.2. Key Industry Events
  • 4.3. Death Rate of CVD in Europe, 2015
  • 4.4. Top Causes of Death in the EU
  • 4.5. Pharmaceutical Expenditure, 2014
  • 4.6. Pharmaceutical Expenditure, 2013

5. Market Dynamics

  • 5.1. Drivers and Restraints Snapshot Analysis
  • 5.2. Drivers
    • 5.2.1. Rise in incidence of coagulation and renal disorders in Europe
    • 5.2.2. Inclination of slaughterhouse owners to enter crude heparin processing business expected to overcome demand-supply gap
    • 5.2.3. Ban on imports from China to boost production in Europe
    • 5.2.4. Commercialization of safe and cost-effective heparin products
  • 5.3. Restraints
    • 5.3.1. Availability of alternative anticoagulants impeding sale of biological heparin products
    • 5.3.2. Enhanced quality control measures and environmental factors elevating the cost of heparin production
    • 5.3.3. Patent loss and increasing use of off-label products
    • 5.3.4. Risk of heparin induced thrombocytopenia
  • 5.4. Opportunities
    • 5.4.1. Biosimilars as an alternative to biological-based products
    • 5.4.2. Research activities on marine-based heparin products
  • 5.5. Opportunity Analysis
  • 5.6. Pricing and Market Projections

6. Europe Heparin Market Analysis, by Product Type

  • 6.1. Key Findings
  • 6.2. Market Value Share Analysis, by Product Type, 2015 and 2024
  • 6.3. Europe Heparin Market Size (US$ Mn) Forecast, by Product, 2014-2024
    • 6.3.1. Low Molecular Weight Heparin
    • 6.3.2. Unfractionated Heparin
    • 6.3.3. Ultra-low Molecular Weight Heparin
  • 6.4. Key Trends
  • 6.5. Market Attractiveness Analysis, by Product, 2015

7. Europe Heparin Market Analysis, by End-user

  • 7.1. Key Findings
  • 7.2. Introduction
  • 7.3. Market Value Share Analysis, by End-user, 2015 and 2024
  • 7.4. Europe Heparin Market Size (US$ Mn) Forecast, by End-user, 2014-2024
    • 7.4.1. Hospitals
    • 7.4.2. Blood and Stem Cell Bank
    • 7.4.3. Others
  • 7.5. Key Trends

8. Europe Heparin Market Analysis, by Country

  • 8.1. Market Value Share Analysis, by Country, 2015 and 2024
  • 8.2. Germany
  • 8.3. France
  • 8.4. U.K.
  • 8.5. Italy
  • 8.6. Spain
  • 8.7. Poland
  • 8.8. Switzerland
  • 8.9. Austria
  • 8.10. Hungary
  • 8.11. Belgium
  • 8.12. Portugal
  • 8.13. Czech Republic
  • 8.14. Greece
  • 8.15. Slovakia
  • 8.16. Rest of Europe
  • 8.17. Market Attractiveness Analysis, by End-user, 2015

9. Competitive Landscape

  • 9.1. Europe Heparin Market Share Analysis, by Company (2015)
  • 9.2. Competition Matrix
    • 9.2.1. Sanofi SA
    • 9.2.2. GlaxoSmithKline plc
    • 9.2.3. Pfizer, Inc.
    • 9.2.4. Leo Pharma
    • 9.2.5. Dr. Reddy's Laboratories
    • 9.2.6. Fresenius SE & Co. KG
    • 9.2.7. Teva Pharmaceutical Industries Ltd.

10. Company Profiles

  • 10.1. Sanofi SA
    • 10.1.1. Company Details
    • 10.1.2. Company Description
    • 10.1.3. Business Overview
    • 10.1.4. SWOT Analysis
    • 10.1.5. Financial Analysis
    • 10.1.6. Strategic Overview
  • 10.2. GlaxoSmithKline plc
    • 10.2.1. Company Details
    • 10.2.2. Company Description
    • 10.2.3. Business Overview
    • 10.2.4. SWOT Analysis
    • 10.2.5. Financial Analysis
    • 10.2.6. Strategic Overview
  • 10.3. Pfizer, Inc.
    • 10.3.1. Company Details
    • 10.3.2. Company Description
    • 10.3.3. Business Overview
    • 10.3.4. SWOT Analysis
    • 10.3.5. Financial Analysis
    • 10.3.6. Strategic Overview
  • 10.4. Leo Pharma
    • 10.4.1. Company Details
    • 10.4.2. Company Description
    • 10.4.3. Business Overview
    • 10.4.4. SWOT Analysis
    • 10.4.5. Financial Analysis
    • 10.4.6. Strategic Overview
  • 10.5. Dr. Reddy's Laboratories
    • 10.5.1. Company Details
    • 10.5.2. Company Description
    • 10.5.3. Business Overview
    • 10.5.4. SWOT Analysis
    • 10.5.5. Financial Analysis
    • 10.5.6. Strategic Overview
  • 10.6. Fresenius SE & Co. KG
    • 10.6.1. Company Details
    • 10.6.2. Company Description
    • 10.6.3. Business Overview
    • 10.6.4. SWOT Analysis
    • 10.6.5. Financial Analysis
    • 10.6.6. Strategic Overview
  • 10.7. Teva Pharmaceutical Industries Ltd.
    • 10.7.1. Company Details
    • 10.7.2. Company Description
    • 10.7.3. Business Overview
    • 10.7.4. SWOT Analysis
    • 10.7.5. Financial Analysis
    • 10.7.6. Strategic Overview

List of Figures

  • FIG. 1: Europe Heparin Market Revenue (US$ Mn), 2015
  • FIG. 2: Europe Heparin Market Size (US$ Mn) Forecast, 2014-2024
  • FIG. 3: Europe Heparin Average Pricing Analysis (US$) 2015-2024
  • FIG. 4: Europe Heparin Market Value Share Analysis By Product, 2016 and 2024
  • FIG. 5: Europe LMWH Market Revenue, (US$ Mn), 2014-2024
  • FIG. 6: Europe Unfractionated Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 7: Europe ULMWH Market Revenue, (US$ Mn), 2014-2024
  • FIG. 8: Europe Heparin Market Value Share Analysis By End-user, 2016 and 2024
  • FIG. 9: Europe Hospitals Heparin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 10: Europe Blood and Stem Cell Bank Heparin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 11: Europe Others (End-user) Heparin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 12: Europe Heparin Market Value Share Analysis, by Country, 2015 and 2024
  • FIG. 13: Germany Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 14: France Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 15: UK Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 16: Italy Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 17: Spain Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 18: Poland Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 19: Switzerland Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 20: Austria Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 21: Hungary Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 22: Belgium Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 23: Portugal Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 24: Czech Republic Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 25: Greece Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 26: Slovakia Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 27: Rest of Europe Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 28: Heparin Market Attractiveness Analysis, by Product, 2015
  • FIG. 29: Heparin Market Attractiveness Analysis, by End-user, 2015
  • FIG. 30: Europe Heparin Market Share Analysis By Company (2015)

List of Tables

  • TABLE 1: Europe Heparin Market Size (US$ Mn) Forecast, By Product, 2016-2024
  • TABLE 2: Europe Heparin Market Size (US$ Mn) Forecast, By End-user, 2016-2024
  • TABLE 3: Europe Heparin Market Size (US$ Mn) Forecast, by Country, 2014-2024
Back to Top